Resources

Adding transcranial magnetic stimulation (TMS) to a psychiatry practice is one of the clearest ways to expand what you can offer patients who have not responded to medication, while building a durable, insurance-reimbursed service line. It is also a real operational project. This guide walks through the decisions that determine whether a TMS program launches smoothly or stalls: the device and business model, the physical space, the staffing and training, the reimbursement path, and the first patients. Each has a dedicated deep-dive linked below; start here for the full picture.

You can build a reasonable estimate of your out-of-pocket TMS cost with five pieces of information: whether you have insurance, how many sessions your course involves, the price range your clinic quotes, your plan's cost-sharing details, and whether prior authorization is already in place. None of these numbers require a financial background to gather — most come directly from your clinic or your insurance card. This guide walks through each input, shows a worked example with clearly labeled illustrative numbers, and explains how to turn the estimate into a real figure.

rTMS, iTBS, and accelerated TMS are three terms that describe how magnetic pulses are delivered during a TMS session — not different brands, devices, or diagnoses. rTMS refers to a steady, repeating pulse pattern delivered over a longer session; iTBS refers to a patterned, theta-burst delivery that compresses a comparable session into a few minutes; and accelerated TMS refers to scheduling multiple sessions in a single day over a compressed number of days, an approach generally made possible by the short session time of iTBS. This article defines each term clearly and shows how they relate to one another, without making claims about comparative effectiveness.

TMS therapy comes with its own vocabulary — protocol names, acronyms, billing terms, and regulatory language that can be confusing to someone encountering it for the first time. This glossary collects the terms most commonly used when discussing TMS, defined plainly and without evaluative claims about effectiveness or safety, so you can use it as a quick reference alongside the other articles on this site.

A denied TMS claim is common and often not final. Most denials come down to a small set of recurring issues — missing prior authorization, incomplete documentation of prior treatment attempts, or a coding or administrative error — and most insurance plans provide a structured appeal process specifically designed to correct these problems. This article walks through why TMS claims typically get denied, how the general appeal process works, and what tends to strengthen an appeal. It describes an administrative process, not legal or clinical advice, and every plan's specific rules and deadlines should be confirmed directly with the insurer.

The two most common TMS coil families—figure-of-8 and M-coil—differ in how they shape the magnetic field, and in how deep that field is designed to reach. A figure-of-8 coil concentrates its field into a small, focal area, roughly the size of a coin, while an M-coil design spreads the induced current across a broader region of tissue. Both designs are grounded in the same electromagnetic physics described in our overview of how a TMS coil works; the difference is purely one of field geometry.This distinction matters for anyone trying to understand TMS equipment, because coil design is often described using language like "deep TMS," which can be misread as meaning the field reaches further into the brain. In physical terms, it doesn't—it reaches a broader area at a similar depth. Below is a plain look at the geometry, field shape, and design trade-offs of each coil type.

TMS therapy costs vary by treatment plan and insurance. Coverage is expanding, while payment plans and financing can make treatment more accessible.

You can model whether a TMS program will pencil out for your practice with four inputs: your average reimbursement per session, your fixed monthly cost, your per-session cost, and your expected monthly session volume. Once you have those four numbers, a single formula tells you the session volume at which the program breaks even, and the same formula lets you compare acquisition models like lease versus pay-per-use at your own realistic volume. This guide walks through each input, gives you the formula in plain language, and works a clearly labeled illustrative example.

Ampa One is a transcranial magnetic stimulation (TMS) system cleared by the FDA for the treatment of Major Depressive Disorder in adult patients. This page answers the operational questions clinic staff ask most often when running the system day to day.

Depression is considered treatment-resistant when a patient has not responded adequately to two or more antidepressant trials at the right dose and duration. At that point, most people move beyond another medication switch and weigh three established options.Transcranial magnetic stimulation (TMS) uses focused magnetic pulses to stimulate specific brain circuits, most often the dorsolateral prefrontal cortex, without anesthesia. Ketamine and esketamine (Spravato) act on NMDA receptors to produce rapid antidepressant effects and support synaptic plasticity, delivered by IV infusion or intranasal spray. Electroconvulsive therapy (ECT) induces a brief, controlled seizure under anesthesia and remains the longest-studied option for severe cases.All three carry FDA recognition for depression. None is experimental. Each has its own published evidence base and its own profile of benefits and burdens. No single option wins for every patient. Your choice turns on practical factors: your treatment history, your tolerance for side effects, the time each demands, and the support you have at home. The sections below work through each one.